PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications

AIMS: Trastuzumab, the first humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2/HER2), is currently used as a first-line treatment for HER2 (+) tumours. However, trastuzumab increases the risk of cardiac complications without affecting myocardial structure, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhifei, Gao, Zizheng, Fu, Huangxi, Zeng, Yan, Jin, Ying, Xu, Bo, Zhang, Yuanteng, Pan, Zezheng, Chen, Xueqin, Zhang, Xiaochen, Wang, Xiaohong, Yan, Hao, Yang, Xiaochun, Yang, Bo, He, Qiaojun, Luo, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202646/
https://www.ncbi.nlm.nih.gov/pubmed/36651911
http://dx.doi.org/10.1093/cvr/cvad012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202646/
https://www.ncbi.nlm.nih.gov/pubmed/36651911
http://dx.doi.org/10.1093/cvr/cvad012

Ejemplares similares